Zyversa TherapeuticsZVSA
13F holders, Q3 2024 (September 30)6holders +2
3new positions
1sold out
$2.36avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Zyversa Therapeutics Inc. (ZVSA) in their 13F filings, up 2 from Q2 2024. 3 opened new positions and 1 sold out. The largest holders were Tower Research Capital LLC (TRC) ($6K), UBS Group AG ($1K) and Bank of America Corp. ($19).
- Company
- Zyversa Therapeutics Inc.
- CUSIP
- 98987D300
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $1K |
| Exits | 1 | $36K |
All 13F filers, Q2 2024 → Q3 2024: 2,354 shares bought and 9,598 shares sold, net −7,244 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Tower Research Capital LLC (TRC) | 0.00% | Add +267.1% | 2,566 | $6K |
| UBS Group AG | 0.00% | New | 433 | $1K |
| Bank of America Corp. | 0.00% | Add +14.3% | 8 | $19 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $2 |
| Morgan Stanley | 0.00% | New | 1 | $2 |
| Royal Bank of Canada | 0.00% | New | 52 | $0 |
"% of holder's portfolio" is ZVSA's weight in each manager's 13F, not the share of Zyversa Therapeutics Inc. the manager owns.